சுருக்கம்

Neoadjuvant therapy pancreatic cancer& breast cancer meta-analysis of randomized controlled trials

Melissa Ferraro

Neoadjuvant chemotherapy is commonly given to patients with non metastatic breast cancer to de-escalate the degree of surgery within the breast and axilla. Tumor science significantly impacts the probability of accomplishing a pathologic total reaction, which has both prognostic and helpful implications. Ongoing clinical trials are evaluating both acceleration and de-escalation of surgery, radiation treatment, and adjuvant systemic treatment based on tumor reaction to neoadjuvant chemotherapy. Neoadjuvant treatment may move forward survival compared with forthright surgery in patients with resectable and borderline resectable pancreatic cancer, but high-quality prove is lacking. We methodicallly looked for randomized trials comparing neoadjuvant treatment with forthright surgery for resectable and borderline resectable pancreatic cancer distributed since database beginning until December 2020. The essential result was in general survival by intention-to-treat with subgroup examinations for resectability